CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Serum levels of 25-Hydroxyvitamin D at diagnosis are not associated with overall survival in esophageal adenocarcinoma
-
June 11 2019
-
-
Source: Cancer Epidemiol Biomarkers Prev.
Details:
-
Alternative Title:Cancer Epidemiol Biomarkers Prev
-
Personal Author:
-
Description:Background:
Higher levels of circulating 25-Hydroxyvitamin D (25(OH)D) are associated with longer survival in several cancers, but the results have differed across cancer sites. The association between serum 25(OH)D levels and overall survival (OS) time in esophageal adenocarcinoma (EA) remains unclear.
Methods:
We utilized serum samples from 476 patients with primary EA, recruited from Massachusetts General Hospital between 1999 and 2015. We used logrank tests to test the difference in survival curves across quartiles of 25(OH)D levels and extended Cox modeling to estimate adjusted hazard ratios (HR). We tested for interactions between clinical stage or BMI on the association between 25(OH)D and overall survival. We additionally performed sensitivity analyses to determine if race or timing of blood draw (relative to treatment) affected these results.
Results:
We found no evidence that survival differed across quartiles of 25(OH)D (logrank p=0.48). Adjusting for confounders, we found no evidence the hazard of death among the highest quartile of 25(OH)D (Quartile 1) differed from any other quartile (Quartile2 HR 0.90, 95% Confidence Interval (CI) 0.67–1.23; Quartile3 HR 1.03, 95% CI 0.76–1.38; Quartile4(lowest) HR 0.98, 95% CI 0.72–1.33). Sensitivity analyses yielded consistent results when accounting for race or time between diagnosis and blood draw. Moreover, we did not find evidence of interaction between 25(OH)D and clinical stage or BMI on OS.
Conclusions:
Serum level of 25(OH)D near time of diagnosis was not associated with OS in EA patients.
Impact:
Screening 25(OH)D levels among EA patients at diagnosis is not clinically relevant to their cancer prognosis based on present evidence.
-
Subjects:
-
Source:
-
Pubmed ID:31186263
-
Pubmed Central ID:PMC6677623
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-425.60 KB]
